Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Number of holders
-
156
-
Total 13F shares, excl. options
-
56,025,691
-
Shares change
-
+1,787,576
-
Total reported value, excl. options
-
$774,315,063
-
Value change
-
+$10,576,060
-
Put/Call ratio
-
84.88%
-
Number of buys
-
69
-
Number of sells
-
-73
-
Price
-
$13.82
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q2 2022
184 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2022.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 156 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 56,025,691 shares
of 104,661,494 outstanding shares and own 53.53% of the company stock.
Largest 10 shareholders include JPMORGAN CHASE & CO (6,687,925 shares), BlackRock Inc. (5,684,831 shares), Capital World Investors (4,590,000 shares), Palo Alto Investors LP (4,405,039 shares), VANGUARD GROUP INC (3,703,055 shares), Polar Capital Holdings Plc (3,117,052 shares), FRANKLIN RESOURCES INC (2,366,367 shares), STATE STREET CORP (1,779,793 shares), JENNISON ASSOCIATES LLC (1,755,703 shares), and BAMCO INC /NY/ (1,683,008 shares).
This table shows the top 156 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.